Results 1 to 10 of about 60,346 (233)

Incidence and determinants of excessive weight gain in people living with HIV initiating tenofovir, lamivudine, and dolutegravir-based therapy: a multicenter retrospective study in northwest Ethiopia [PDF]

open access: goldFrontiers in Pharmacology
BackgroundThe incidence and nature of excessive weight gain associated with antiretroviral treatment using tenofovir, lamivudine, and dolutegravir based regimens among patients living with human immunodeficiency virus has not been properly examined in ...
Gashaw Sisay Chanie   +7 more
doaj   +2 more sources

Development and validation of a normal-phase HPTLC method for the simultaneous analysis of Lamivudine and Zidovudine in fixed-dose combination tablets

open access: goldJournal of Pharmaceutical Analysis, 2012
Simultaneous quantification of Lamivudine and Zidovudine in tablets by HPTLC method was developed and validated. The chromatograms were developed using a mobile phase of toluene:ethyl acetate:methanol (4:4:2, v/v/v) on pre-coated plate of silica gel GF ...
Palani Venkatesh, Mahesh Daggumati
doaj   +2 more sources

52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic Hepatitis B [PDF]

open access: yes, 2013
Background and Aims: The Roadmap concept is a therapeutic framework in chronic hepatitis B for the intensification of nucleoside analogue monotherapy based on early virologic response.
Aldo Trylesinski   +41 more
core   +24 more sources

Tratamiento prolongado con interferón alfa-2b más lamivudina en pacientes con hepatitis crónica B y antígeno e positivo Prolonged treatment with alpha-2b interferon plus lamivudine in patients with e antigen positive chronic hepatitis B

open access: greenRevista Cubana de Medicina, 2007
Las tasas de seroconversión del antígeno e alcanzadas con los antivirales actuales no sobrepasan el 35 %. La combinación de inmunomodulador y antiviviral ha sido teóricamente la estrategia más aceptada en los últimos años; sin embargo, los resultados en ...
Eduardo Vilar Gómez   +4 more
doaj   +1 more source

Putative Repurposing of Lamivudine, a Nucleoside/Nucleotide Analogue and Antiretroviral to Improve the Outcome of Cancer and COVID-19 Patients

open access: yesFrontiers in Oncology, 2021
Lamivudine, also widely known as 3TC belongs to a family of nucleotide/nucleoside analogues of cytidine or cytosine that inhibits the Reverse Transcriptase (RT) of retroviruses such as HIV.
José J. García-Trejo   +2 more
doaj   +1 more source

Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection. [PDF]

open access: yesPLoS ONE, 2016
Sequential addition of tenofovir disoproxil fumarate (TDF) is often needed for patients coinfected with HIV and hepatitis B virus (HBV) who develop HBV resistance to lamivudine after combination antiretroviral therapy (cART) containing only lamivudine ...
Yu-Shan Huang   +9 more
doaj   +1 more source

Removal of lamivudine from synthetic solution using jamun seed (Syzygium cumini) biochar adsorbent

open access: yesEmerging Contaminants, 2023
Antiviral drugs such as lamivudine have been globally identified in the environment and marked as emerging pollutants of concern due to their bioactive extremity.
Asha Ripanda   +7 more
doaj   +1 more source

Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus. [PDF]

open access: yesPLoS ONE, 2016
In the fall of 2014, an international news agency reported that patients suffering from Ebola virus disease (EVD) in Liberia were treated successfully with lamivudine, an antiviral drug used to treat human immunodeficiency virus-1 and hepatitis B virus ...
Yu Cong   +35 more
doaj   +1 more source

Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)

open access: yesEBioMedicine, 2020
: Background: We investigated the efficacy of a switch to dolutegravir plus lamivudine in aviremic individuals without evidence of persistent lamivudine resistance-associated mutations in baseline proviral DNA population sequencing. Methods: Open-label,
Rosa De Miguel   +21 more
doaj   +1 more source

Home - About - Disclaimer - Privacy